Designing fecal microbiota transplant trials that account for differences in donor stool efficacy

Statistical Methods in Medical Research

Volumn 27, Issue 10, 2018, Pages 2906-2917

  Olesen, Scott W ^a   Gurry, Thomas ^a   Alm, Eric J ^a,b  

^a Massachusetts Institute of Technology   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Adaptive design; Bayesian statistics; clinical trials; fecal microbiota transplant; inflammatory bowel disease

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; CALCULATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; DONOR; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; SIMULATION; ULCERATIVE COLITIS; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; TREATMENT OUTCOME;

BAYES THEOREM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85043287826     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280216688502     Document Type: Article

References (28)

1. Cohen SH, Gerding DN, Johnson S, Clinical practice guidelines for Clostridium difficile infection in adults. Infect Control Hosp Epidemiol 2010; 31: 431–455
2. van Nood E, Vrieze A, Nieuwdorp M, Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–415
3. Kelly CP, LaMont JT. Clostridium difficile – more difficult than ever. N Engl J Med 2008; 359: 1932–1940
4. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2015; 2. DOI: 10.1093/ofid/ofv0041
5. Li SS, Zhu A, Benes V, Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016; 352: 586–589
6. Kassam Z, Lee CH, Yuan Y, Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500–508
7. Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 2016; 13: 508–516
8. Smits LP, Bouter KEC, de Vos WM, Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946–953
9. Sadowsky MJ, Khoruts A. Faecal microbiota transplantation is promising but not a panacea. Nat Microbiol 2016; 1. DOI: 10.1038/nmicrobiol.2016.15
10. Moayyedi P, Surette MG, Kim PT, Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149: 102–109.e6
11. Cook TD, DeMets DL. Introduction to statistical methods for clinical trials, Boca Raton, Florida, USA: Chapman & Hall/CRC, 2008
12. Bartlett RH, Roloff DW, Cornell RG, Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics 1985; 76: 479–487
13. Chow S-C, Chang M. Adaptive methods in clinical trials, Boca Raton, Florida, USA: Chapman & Hall/CRC, 2007
14. Hahn T. Cuba – a library for multidimensional numerical integration. Comput Phys Commun 2005; 168: 78–95
15. Tange O. Gnu parallel – the command-line power tool. login USENIX Mag 2011; 36: 42–47
16. Berry DA, Fristedt B. Bandit problems: sequential allocation of experiments, Dordrecht, Netherlands: Springer, 1985
17. Rossen NG, Fuentes S, van der Spek MJ, Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149: 110–118
18. Trippa L, Lee EQ, Wen PY, Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 2012; 30: 3258–3263
19. Villar SS, Wason J, Bowden J. Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule. Biometrics 2015; 71: 969–978
20. Hung JHM, O’Neill RT, Wang S-J, A regulatory view of adaptive/flexible clinical trial design. Biom J 2006; 48: 565–573
21. Wei LJ, Smythe RT, Lin DY, Statistical inference with data-dependent treatment allocation rules. J Am Stat Assoc 1990; 85: 156–162
22. Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc 1978; 73: 840–843
23. Zelen M. Play the winner rule and the controlled clinical trial. J Am Stat Assoc 1969; 64: 131–146
24. Wei LJ. The generalized Polya’s urn design for sequential medical trials. Ann Stat 1979; 7: 291–296
25. Su C, Lichtenstein GR, Krok K, A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s disease. Gastroenterology 2004; 126: 1257–1269
26. Su C, Lewis JD, Goldberg B, A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516–526
27. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–413
28. Cheng Y, Berry DA. Optimal adaptive randomized designs for clinical trials. Biometrika 2007; 94: 673–689